Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half
Analysts Highlight Potential Growth Opportunities
Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.
